hCG vs Leuprolide

Glycoprotein hormone binding LH receptor on Leydig cells; stimulates testosterone production; prevents testicular atrophy during TRT; maintains spermatogenesis via FSH-like activity

Human chorionic gonadotropin (hCG) is a glycoprotein hormone that acts as a functional analogue of luteinizing hormone (LH), binding to LH receptors on Leydig cells in the testes and granulosa cells in the ovaries to stimulate steroidogenesis. In men, hCG stimulates testicular testosterone production directly, making it a widely used clinical tool for hypogonadotropic hypogonadism, male fertility support, and preservation of testicular function alongside testosterone replacement therapy. Clinical research demonstrates hCG effectiveness for improving testosterone levels and sperm parameters in males with gonadotropin deficiency, as well as for triggering final oocyte maturation in IVF protocols. hCG is an FDA-regulated biologic available in multiple approved formulations; use requires physician supervision due to dose-dependent effects on testosterone, estradiol, and reproductive signaling. hCG dosage in TRT support: in men using testosterone replacement therapy, hCG is prescribed to prevent testicular atrophy and maintain intratesticular testosterone levels needed for spermatogenesis. Typical clinical doses range from 250 to 500 IU subcutaneously administered 2–3 times per week, though protocols vary by provider and individual response. At higher doses, hCG's stimulation of testicular testosterone can also increase aromatization to estradiol — a clinically relevant consideration in TRT management requiring estrogen monitoring. hCG vs gonadorelin: both are used in men's health for testicular preservation alongside TRT, but they act at different axis levels. hCG acts directly on Leydig cell LH receptors, bypassing the pituitary entirely — a direct trophic signal to the testes. Gonadorelin acts upstream at the pituitary to stimulate endogenous LH and FSH release, preserving the full hypothalamic-pituitary-gonadal axis including FSH-driven spermatogenesis. For men prioritizing sperm production, gonadorelin's preservation of FSH signaling offers a potential advantage; for men primarily focused on testicular volume and intratesticular testosterone maintenance, hCG provides a well-validated, direct approach. Telehealth and men's health providers offering hCG and gonadorelin protocols are listed in the PeptideBase directory.

Continuous GnRH receptor stimulation causes receptor desensitization and downregulation. This suppresses LH/FSH → testosterone/estrogen to castrate levels. Short-term pulsatile use can transiently stimulate the axis before suppression occurs.

Leuprolide (leuprorelin; Lupron) is a synthetic nonapeptide GnRH agonist (D-Leu6, des-Gly10-GnRH ethylamide) designed as a superagonist of the gonadotropin-releasing hormone receptor; paradoxically, its continuous non-pulsatile receptor occupation produces profound hypogonadotropism by causing receptor downregulation and pituitary desensitization — the opposite effect of endogenous pulsatile GnRH release — resulting in medical castration levels of sex steroids. Continuous LHRH receptor agonism initially produces a testosterone or estrogen flare before pituitary downregulation suppresses LH and FSH secretion, reducing testosterone to castrate levels in men and estrogen to postmenopausal levels in women within 2–4 weeks; this chemical hypogonadism forms the basis for its use across hormone-sensitive conditions including prostate cancer, endometriosis, uterine fibroids, and central precocious puberty. A landmark randomized controlled trial published in the New England Journal of Medicine compared leuprolide against diethylstilbestrol for metastatic prostate cancer and demonstrated equivalent efficacy with a markedly superior cardiovascular side-effect profile, establishing the pivotal evidence base that led to FDA approval and positioned GnRH agonists as the preferred hormonal therapy for prostate cancer. Leuprolide (Lupron, AbbVie; and generic formulations) is FDA-approved and requires a prescription; approved indications include advanced prostate cancer, endometriosis, uterine fibroids, central precocious puberty, and other hormone-sensitive conditions; it is available as daily subcutaneous injection, monthly depot, and multi-month depot formulations.